Hyper-CVAD

DRUG4 trials

Conditions

Acute Lymphoblastic LeukemiaAdult T-cell Leukemia/LymphomaB-cell Acute Lymphocytic LeukemiaBi-Phenotypic LeukemiaBurkitt LymphomaHematopoietic Stem Cell MobilizationLymphoblastic LymphomaLymphoid Malignancies (New or Relapsed)

Early Phase 1

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

CompletedNCT01184885

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityAcute Lymphoblastic Leukemia, Adult T-cell Leukemia/Lymphoma, Burkitt Lymphoma +3

Start: 2010-07-31End: 2013-04-30Updated: 2025-05-04

Phase 1

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

RecruitingNCT06287229

M.D. Anderson Cancer CenterB-cell Acute Lymphocytic Leukemia, Relapsed/Refractory

Start: 2024-07-11End: 2030-12-31Target: 40Updated: 2026-02-17

A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias

RecruitingNCT06466395

M.D. Anderson Cancer CenterBi-Phenotypic Leukemia, Refractory Acute Leukemia, Relapsed Acute Leukemia +1

Start: 2025-02-18End: 2031-12-31Target: 22Updated: 2026-03-09

Phase 3

Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

RecruitingNCT06520163

The Affiliated People's Hospital of Ningbo UniversityHematopoietic Stem Cell Mobilization, Non-Hodgkin's Lymphoma

Start: 2024-08-01End: 2026-08-31Target: 99Updated: 2025-12-04

Related Papers

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.

Blood2025-11-03

Etoposide-cytarabine-pegfilgrastim (EAP) and disease-specific chemotherapy regimens for hematopoietic stem cell mobilization in lymphoma: A randomized phase III trial